Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Bank of Montreal Can

Bank of Montreal Can decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 6.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 201,099 shares of the medical equipment provider's stock after selling 13,328 shares during the quarter. Bank of Montreal Can owned about 0.10% of Zimmer Biomet worth $21,763,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ZBH. Brown Brothers Harriman & Co. boosted its holdings in shares of Zimmer Biomet by 12.1% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,806 shares of the medical equipment provider's stock worth $195,000 after purchasing an additional 195 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Zimmer Biomet by 6.9% during the third quarter. Daiwa Securities Group Inc. now owns 25,133 shares of the medical equipment provider's stock worth $2,713,000 after buying an additional 1,618 shares in the last quarter. Larson Financial Group LLC boosted its stake in Zimmer Biomet by 61.9% during the third quarter. Larson Financial Group LLC now owns 3,407 shares of the medical equipment provider's stock worth $368,000 after buying an additional 1,302 shares during the last quarter. Cerity Partners LLC grew its holdings in Zimmer Biomet by 28.7% in the 3rd quarter. Cerity Partners LLC now owns 40,307 shares of the medical equipment provider's stock valued at $4,351,000 after buying an additional 8,999 shares in the last quarter. Finally, Studio Investment Management LLC increased its stake in shares of Zimmer Biomet by 52.1% in the 3rd quarter. Studio Investment Management LLC now owns 17,373 shares of the medical equipment provider's stock worth $1,880,000 after acquiring an additional 5,953 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.1 %

ZBH stock traded up $0.08 during midday trading on Friday, hitting $112.10. The company's stock had a trading volume of 504,058 shares, compared to its average volume of 1,527,881. The firm has a 50-day simple moving average of $107.29 and a 200-day simple moving average of $109.38. The firm has a market capitalization of $22.32 billion, a P/E ratio of 21.31, a PEG ratio of 2.06 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts' expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.65 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ZBH shares. TD Cowen lowered their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating on the stock in a research report on Friday, September 6th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. UBS Group decreased their price objective on Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating on the stock in a report on Thursday, August 8th. Finally, Robert W. Baird cut their target price on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.